| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 507801 | 1 mg | $160 | ||
| 507802 | 5 mg | $400 | ||
| 507803 | 25 mg | $1100 |
| Clone | 10F.9G2.1 |
|---|---|
| Application | ELISA, WB, Flow cytometry, IHC, ICC, animal model study |
| Host Species | CHO cells |
| Reactivity | Mouse |
| Format | Liquid |
| Target Name | mouse PD-L1, CD274 |
| Product Description | In Vivo Grade Recombinant Anti-mouse PD-L1 Monoclonal Antibody |
| Isotype | Rat IgG2b Kappa |
| Antibody Type | Recombinant |
| Regulatory Status | RUO |
| Purity | >95% by reducing SDS-PAGE |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Storage Conditions | 4ºC |
| Grade | In vivo |
| Recommended Usage | This product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment. |
| RRID | AB_3739352 |
| See All Formats | Clone 10F.9G2.1 |
Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a transmembrane protein that plays a pivotal role in immune regulation by modulating T cell activity. PD-L1 is expressed on a wide range of cells, including antigen-presenting cells, epithelial cells, and many tumor cells. Its primary function is to bind to its receptor, programmed cell death protein 1 (PD-1), located on activated T cells. This interaction delivers an inhibitory signal that reduces T cell proliferation, cytokine production, and cytotoxicity, thereby maintaining immune homeostasis and preventing autoimmunity. However, in pathological contexts such as cancer, PD-L1 expression allows tumor cells to evade immune attack, creating an immunosuppressive microenvironment.
Structurally, PD-L1 is a type I transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules. The extracellular domain comprises two immunoglobulin-like regions—an IgV-like domain responsible for PD-1 binding and an IgC-like domain that stabilizes the molecule. The protein also contains a single transmembrane helix and a short cytoplasmic tail that lacks classical signaling motifs but may interact with intracellular partners influencing its stability and localization. The PD-L1–PD-1 complex adopts a well-characterized interface where the IgV domains of both molecules interact in a way that blocks T cell receptor-mediated activation signaling.
The main ligands of PD-L1 are PD-1 and CD80 (B7-1). While PD-1 engagement results in T cell inhibition, interaction with CD80 may yield bidirectional signaling effects depending on the cellular context. PD-L1 can be induced by inflammatory cytokines such as interferon-gamma (IFN-γ), linking innate immune responses to immune checkpoint modulation.
PD-L1 plays a major role in numerous diseases. Overexpression of PD-L1 is a hallmark of many cancers, including lung, melanoma, renal, and breast cancers, where it contributes to immune escape. Therapeutically, blocking the PD-1/PD-L1 axis with immune checkpoint inhibitors has revolutionized cancer treatment. Drugs such as pembrolizumab, nivolumab, and atezolizumab disrupt this inhibitory pathway, restoring antitumor T cell function. Moreover, PD-L1 is being explored as both a predictive biomarker for immunotherapy response and a target for novel therapies, including bispecific antibodies and CAR-T cells aimed at enhancing immune-mediated tumor clearance.
In Vivo Star Anti-Mouse CD274 (PD-L1) Antibody TDS
Anti-Human PD-1 (Camrelizumab Biosimilar), Clone Camrelizumab
Anti-Human PD-1 (Cemiplimab Biosimilar), Clone Cemiplimab
Anti-Human PD-1 (Nivolumab Biosimilar), Clone Nivolumab
Anti-Human PD-1 (Pembrolizumab Biosimilar), Clone Pembrolizumab
Human PD-L1 (CD274) Protein (C-His)
Human PD-L1 (CD274) Protein (C-His-Avi)
Biotin Human PD-L1 (CD274) Protein (C-His-Avi)
Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2
Biotin Anti-Mouse CD274 (PD-L1) Antibody, Clone 10F.9G2
Anti-Human PD-L1 (Atezolizumab Biosimilar), Clone Atezolizuma
Have a product or application question? Consult our FAQs or contact us.
